FUNDING SIGNALS

Real Signals. Real Leads. Real Deals.

The only platform that turns real-time signals into your perfect leads

Know Who, Why, and When to reach out — instantly.

FundzWatch™ AI Scoring

10-25 leads daily

Real-time alerts

★★★★★

4.8/5 on G2• High Performer Fall 2025

Used by teams at LinkedIn, HubSpot & Oracle

🔒 app.fundz.net

TechCorp

📍 San Francisco👥 85

Post-Funding

⭐ Ideal Match

Just raised $40M Series B - high purchase intent window

Accro Bioscience Inks Over $50M Series B Round

Jan 05, 2022•over 3 years ago

Amount Raised

$50 Million

Round Type

series b

Suzhou

Description

Accro Bioscience (Suzhou) Co., LTD. ("Accro Bioscience"), a China-based leading biotechnology company, announced that the company has recently raised over $50 million in an oversubscribed Series B round. The financing was led by Hongtai Aplus with participation from South China Venture Capital, Shenzhen Capital Group, Suzhou Oriza Holdings, and others.

Company Information

Company

Accro Bioscience

Location

Suzhou, Jiangsu, China

About

Accro Bioscience was established in late 2017 and raised exclusive series A investment from Morningside Ventures. The company's research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis, which are associated with major human diseases. Accro Bioscience's core R&D team has over 10 years of experience in biological research in regulated cell death and medicinal chemistry. Dr. Xiaohu Zhang, co-founder and CEO of Accro Bioscience, is a pharmaceutical industry veteran and previously served as the Executive Director at BioDuro/PDD China, Dr. Sudan He, co-founder, and scientific consultant at Accro, is a distinguished scholar. SOURCE Accro Bioscience

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech